IDH2 R172 mutations occur in ~30% of AITL (TFH-derived PTCL). Enasidenib monotherapy acti...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH2-R172K-AITL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AITL |
| Sources | SRC-CIVIC SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH2 R172K (or R172 hotspot) |
| Disease | DIS-AITL |
| ESCAT tier | IIIA |
| Recommended combinations | enasidenib (off-label R/R AITL) |
| Evidence summary | IDH2 R172 mutations occur in ~30% of AITL (TFH-derived PTCL). Enasidenib monotherapy active in IDH2-mut AITL (small case series; Lemonnier et al. Blood 2016 / 2021). NCCN supports off-label use in R/R IDH2-mut AITL. |
Notes
ESCAT IIIA. AITL frontline still CHOP/CHOEP; brentuximab + CHP for CD30+ disease (ECHELON-2).
Used By
No reverse references found in the YAML corpus.